TORQUR

Torqur is a Swiss clinical-stage biotech company launched in 2021 as a subsidiary of Swiss Rockets, a Basel-based incubator and accelerator of start-up companies in oncology and infectiology... Torqur is establishing the platform for discovery and efficient development of innovative anti-cancer therapies targeting the metabolic PI3K/mTOR intracellular signalling pathway. PI3K/mTOR intracellular signalling pathway is often abnormally activated and has a significant role in cancer formation. The lead candidate bimiralisib is a balanced pan-PI3K/mTOR inhibitor formulated for oral and topical administration. Promising early clinical activity has been demonstrated in multiple phase 1/2 studies allowing further development towards proof-of-concept studies in various oncology and dermatology indications. Torqur is strengthening its pipeline by investing in the development of next-generation PI3K/mTOR inhibitors to form a robust portfolio of therapeutic areas in oncology and beyond... Torqur..

Also known as: Torqur AG

Primary location: Basel Switzerland